BEDFORD, Mass., July 03, 2025 - Anika Therapeutics, Inc. $(ANIK)$ has announced the granting of non-statutory stock options to a newly hired non-executive employee as part of their compensation package. On July 1, 2025, Anika issued options for 2,500 shares of common stock at an exercise price of $10.53 per share, reflecting the closing price on the Nasdaq Global Select Market on the grant date. This grant, made under the Anika Therapeutics, Inc. 2021 Inducement Plan and approved by the compensation committee, aims to provide material inducement for the employee's acceptance of their role. The options will vest over three years, with one-third vesting each year, contingent on continuous service. The options are set to expire ten years from the grant date unless terminated earlier under specific terms.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。